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SUPPLEMENTAL TABLE 4 Case Deﬁnitions for DBMD for MD STARnet
Case Deﬁnition
Deﬁnite Documented clinical symptoms referable to a dystrophinopathy and direct support of the diagnosis by at least 1 of the following criteria:
(1) DNA analysis demonstrating a dystrophin mutation.
(2) A muscle biopsy demonstrating abnormal dystrophin, by either immunostaining or Western blot analysis. If there is a family history
demonstrating X-linked inheritance, no additional information is required on the muscle. If the diagnosis is based solely on Western blot
analysis ofmuscle biopsy and clinical symptoms, then theremust be a description that allows conﬁrmation that adequate numbers of intact
muscle ﬁbers were present in the sample to interpret the dystrophin results. If the diagnosis is based on immunostaining, supporting
evidence is required from additional stains, for example, utrophin, spectrin, neuronal nitric oxide synthase, or dystroglycans.
(3) An elevated creatine kinase, an X-linked pedigree, and an affected family member who meets criterion 1 or 2 above.
Probable Elevated creatine kinase, a family history consistent with an X-linked muscular dystrophy and documented clinical symptoms referable to
a dystrophinopathy. Cases that have abnormal dystrophin results on muscle biopsy but lack the data required in the deﬁnition of deﬁnite
cases, above, are called probable.
Possible Elevated creatine kinase and documented clinical symptoms referable to a dystrophinopathy, but no muscle biopsy data, dystrophin mutation
analysis, or family history to support the diagnosis. Cases that do not have creatine kinase information available in the clinical record, and
who do not meet criteria for deﬁnite case, are called possible.
Asymptomatic No clinical symptoms referable to a dystrophinopathy, but laboratory results and/or a positive family history that will likely result in the
development of a dystrophinopathy phenotype.
Female Onset of clinical symptoms referable to a dystrophinopathy appearing before age 21 y and either
(1) a dystrophin mutation or
(2) a muscle biopsy demonstrating abnormal dystrophin as required for deﬁnite case.
SUPPLEMENTAL TABLE 5 Prevalence for DMD and BMD (Deﬁnite, Probable, Possible, and
Asymptomatic Cases; n 5 704) per 10 000 Boys, Ages 5 to 9 Years,
Identiﬁed by MD STARnet, 1991–2010
Quinquennium Cases Population Prevalence 95% CI
All cases 1991–1995 167 778 716 2.14 (1.83–2.50)
1996–2000 200 869 321 2.30 (1.99–2.64)
2001–2005 190 879 300 2.16 (1.86–2.49)
2006–2010 147 942 791 1.56 (1.32–1.83)
Race/ethnicity
Non-Hispanic white 1991–1995 111 538 981 2.06 (1.69–2.48)
1996–2000 121 537 239 2.25 (1.87–2.69)
2001–2005 109 512 206 2.13 (1.75–2.57)
2006–2010 89 504 201 1.77 (1.42–2.17)
Non-Hispanic black 1991–1995 10 121 965 0.82 (0.39–1.51)
1996–2000 19 139 199 1.36 (0.82–2.13)
2001–2005 14 135 329 1.03 (0.57–1.74)
2006–2010 11 144 476 0.76 (0.38–1.36)
Hispanic 1991–1995 29 88 570 3.27 (2.19–4.70)
1996–2000 43 141 042 3.05 (2.21–4.11)
2001–2005 43 176 768 2.43 (1.76–3.28)
2006–2010 28 220 040 1.27 (0.85–1.84)
Phenotype
DMD 1991–1995 125 778 716 1.61 (1.34–1.91)
1996–2000 141 869 321 1.62 (1.37–1.91)
2001–2005 149 879 300 1.69 (1.43–1.99)
2006–2010 113 942 791 1.20 (0.99–1.44)
BMD 1991–1995 42 778 716 0.54 (0.39–0.73)
1996–2000 58 869 321 0.67 (0.51–0.86)
2001–2005 39 879 300 0.44 (0.32–0.61)
2006–2010 32 942 791 0.34 (0.23–0.48)
CI, conﬁdence interval.
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SUPPLEMENTAL TABLE 6 Prevalence in 2010 for DMD and BMD (Deﬁnite, Probable, Possible, and
Asymptomatic Cases; n 5 561) per 10 000 Male Individuals, Ages 5 to
24 Years, Identiﬁed by MD STARnet, 1991–2010
Age Group, y Cases Population Prevalence 95% CI
All cases
All 561 3 827 532 1.47 (1.35–1.59)
20–24 102 960 866 1.06 (0.87–1.29)
15–19 168 985 263 1.71 (1.46–1.98)
10–14 161 938 612 1.72 (1.46–2.00)
5–9 130 942 791 1.38 (1.15–1.64)
Race/ethnicity
Non-Hispanic white All 328 2 147 039 1.53 (1.37–1.70)
20–24 65 564 779 1.15 (0.89–1.47)
15–19 98 558 178 1.76 (1.43–2.14)
10–14 88 519 881 1.69 (1.36–2.09)
5–9 77 504 201 1.53 (1.21–1.91)
Non-Hispanic black All 44 605 232 0.73 (0.53–0.98)
20–24 4 143 512 0.28 (0.08–0.71)
15–19 18 166 175 1.08 (0.64–1.71)
10–14 11 151 069 0.73 (0.36–1.30)
5–9 11 144 476 0.76 (0.38–1.36)
Hispanic All 125 797 913 1.57 (1.30–1.87)
20–24 22 185 830 1.18 (0.74–1.79)
15–19 38 192 816 1.97 (1.39–2.71)
10–14 38 199 227 1.91 (1.35–2.62)
5–9 27 220 040 1.23 (0.81–1.79)
Phenotype
DMD All 410 3 827 532 1.07 (0.97–1.18)
20–24 69 960 866 0.72 (0.56–0.91)
15–19 117 985 263 1.19 (0.98–1.42)
10–14 125 938 612 1.33 (1.11–1.59)
5–9 99 942 791 1.05 (0.85–1.28)
BMD All 147 3 827 532 0.38 (0.32–0.45)
20–24 33 960 866 0.34 (0.24–0.48)
15–19 50 985 263 0.51 (0.38–0.67)
10–14 34 938 612 0.36 (0.25–0.51)
5–9 30 942 791 0.32 (0.21–0.45)
CI, conﬁdence interval.
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